Transforming Growth Factor beta3 (TGF beta 3)

A TGF-beta subtype that plays role in regulating epithelial-mesenchymal interaction during embryonic development. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta3 and TGF-beta3 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor.

Also Known As:

Networked: 301 relevant articles (10 outcomes, 49 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ferguson, Mark W J: 5 articles (08/2009 - 10/2005)
2.	O'Kane, Sharon: 5 articles (08/2009 - 03/2007)
3.	Catherino, William H: 4 articles (03/2010 - 07/2004)
4.	Garcia-Closas, Montserrat: 3 articles (04/2014 - 06/2010)
5.	Malik, Minnie: 3 articles (03/2010 - 09/2008)
6.	Martínez-Alvarez, Concepción: 3 articles (04/2008 - 05/2002)
7.	Murray, Jeffrey C: 3 articles (08/2005 - 05/2003)
8.	Longaker, M T: 3 articles (07/2001 - 11/2000)
9.	Rienhoff, Hugh Young: 2 articles (08/2014 - 08/2013)
10.	Brinton, Louise A: 2 articles (04/2014 - 06/2010)

Related Diseases

1.	Cicatrix (Scar) 08/01/2009 - "Extensive research into the mechanisms of scar-free and scar-forming healing has provided a robust scientific rationale for the development of avotermin (human recombinant TGF-beta3) as a potential therapeutic for the improvement of scar appearance in humans. " 03/01/1995 - "This study also suggests a novel therapeutic use of exogenous recombinant, TGF-beta 3 as an anti-scarring agent." 06/01/2010 - "Microarray analysis showed that TGF-beta3, an essential marker for preventing scarring, was upregulated and expressed for 2 weeks postoperatively. " 08/01/2009 - "As recombinant human TGF-beta3 (avotermin) is being developed for the improvement of scarring in the skin it is important to understand the role, if any, of this cytokine in tumour progression. " 04/11/2009 - "Research into mechanisms of skin scarring identified transforming growth factor beta3 (TGFbeta3) as a potential antiscarring therapy. "
2.	Neoplasms (Cancer) 08/01/1998 - "Experimental studies with TGF-beta 3, a potent negative regulator of epithelial and haematopoietic stem cell growth, have shown that it is possible to temporarily arrest oral mucosal basal cell proliferation, and could therefore offer a new effective and safe form of preventative intervention for patients about to undergo aggressive regimens of cancer therapy." 12/28/2012 - "These studies identify IL-1B and TGFB3 as pro-invasive factors in NSCLC and potential therapeutic targets for tumor progression." 10/01/2010 - "On the top 500 list, several cancer-related genes with an unrecognized role in VSs were down-regulated: CAV1, TGFB3, VCAM1, GLI1, GLI2, PRKAR2B, EPHA4, and FZD1. " 08/01/2009 - "TGF-beta3 and cancer: a review." 04/18/2008 - "In tumors arising in RB-positive livers, Cdkn2d and Tgfb1 were repressed and Cdkn2c, Tgfb2, Tgfb3 and Pai1 were induced, whereas in RB-negative tumors, only Cdkn2c and Tgfb3 were induced. "
3.	Breast Neoplasms (Breast Cancer) 06/01/2011 - "Here associations with risk of invasive breast cancer are assessed for single-nucleotide polymorphisms (SNP) tagging 17 genes in the canonical TGF-β ALK5/SMADs 2&3 and ALK1/SMADs 1&5 signaling pathways: LTBP1, LTBP2, LTBP4, TGFB1, TGFB2, TGFB3, TGFBR1(ALK5), ALK1, TGFBR2, Endoglin, SMAD1, SMAD2, SMAD3, SMAD4, SMAD5, SMAD6, and SMAD7 [Approved Human Gene Nomenclature Committee gene names: ACVRL1 (for ALK1) and ENG (for Endoglin)]. " 05/15/1999 - "Our data support the hypothesis that methylation of a limited number of CpGs at the periphery of an otherwise unmethylated CpG island underlies the transcriptional repression of the downstream promoter in non-breast cancer cells, thereby serving to regulate the use of alternative promoters for TGF-beta3." 11/01/2000 - "The fact that it has been reported previously that high TGF beta 3 plasma levels in patients with untreated early stage breast cancer were correlated with subsequent lymph node metastasis and it was observed in the present study too, that TGF beta 3 expression in breast tumours was an independent predictor of overall survival, led us to suggest that the simultaneous measurement of TGF beta 3 in plasma and its expression in resected tumour tissues in the same cohort of patients may prove to be an important parameter in assessing tumour progression." 10/23/1998 - "Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer." 05/15/1999 - "Activation of an alternative downstream promoter, leading to the production of a truncated mRNA lacking the portion of the 5' noncoding region responsible for translational inhibition of TGF-beta3 mRNA, is only evident in breast cancer cells. "
4.	Mucositis 06/01/1999 - "TGF-beta3 mouthwashes were well tolerated and deserve further study in preventing chemotherapy-induced mucositis." 06/01/1999 - "The purpose of this study was to establish the safety and tolerability of recombinant transforming growth factor-beta3 (TGF-beta3; CGP 46614) mouthwashes intended for prevention of chemotherapy-induced mucositis. " 02/01/2005 - "Keratinocyte growth factor, molgromastim, and transforming growth factor beta3 may also reduce chemotherapy-induced mucositis. " 01/01/1997 - "Administration of topical TGF-beta 3 prior to chemotherapy with 5-fluorouracil (5-FU) significantly reduced the severity of mucositis with respect to time, reduced chemotherapy-associated weight loss and increased survival." 10/01/2000 - "Data from trials in animal models and preliminary data in patients indicate that cytokines such as interleukin-1, interleukin-11, TGF-beta 3 and keratinocyte growth factor could reduce the incidence of mucositis. "
5.	Pre-Eclampsia (Preeclampsia) 04/01/2002 - "Of clinical significance, umbilical cords from pregnancies complicated by pre-eclampsia, showed a significant reduction in total TGF-beta 3 protein expression when compared to those of age-matched patients. " 01/01/2002 - "Recent data obtained from studies on placenta suggest that temporal changes in expression of TGF-beta3 play a key role in trophoblast invasion and that over-expression of TGF-beta3 in pre-eclampsia is responsible for inadequate trophoblast invasion. " 04/01/2002 - "Our data demonstrate that during umbilical cord development TGF-beta 3 expression is spatially and temporally regulated and that TGF-beta 3 expression is altered in umbilical cords of pregnancies complicated by pre-eclampsia. " 04/01/2002 - "TGF-beta 3 expression during umbilical cord development and its alteration in pre-eclampsia." 06/01/1999 - "We speculate that a failure to downregulate expression of TGF-beta 3 at around 9 weeks' gestation results in shallow trophoblast invasion and predisposes the pregnancy to preeclampsia."

Related Drugs and Biologics

1.	Transforming Growth Factor beta1 (TGF beta 1)
2.	Transforming Growth Factor beta (TGF-beta)
3.	Transforming Growth Factor beta2
4.	Transforming Growth Factors (Transforming Growth Factor)
5.	Collagen
6.	Fibronectins (Fibronectin)
7.	Fluorouracil (Carac)
8.	Messenger RNA (mRNA)
9.	Protein Isoforms (Isoforms)
10.	Intercellular Signaling Peptides and Proteins (Growth Factors)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Sutures (Suture)
3.	Transplants (Transplant)
4.	Stents
5.	Homologous Transplantation (Allograft)